K Number
K103480
Device Name
THORACIC VCAR
Date Cleared
2011-03-07

(101 days)

Product Code
Regulation Number
892.2050
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP Authorized
Intended Use
Thoracic VCAR is a CT, non-invasive image analysis software package, which may be used in conjunction with CT lung images to aid in the assessment of thoracic disease diagnosis and management. The software will provide automatic segmentation of the lungs and automatic segmentation and tracking of the airway tree. The software will provide quantification of Hounsfield units and display by color the thresholds within a segmented region.
Device Description
Thoracic VCAR is a CT post-processing software for the GE Advantage Workstation (AW) platform. It is designed for the analysis and processing of volumetric CT chest data. It provides quantitative information to aid in the assessment of respiratory diseases. The primary features of the software are: lung and lobe segmentation to obtain threshold based volume measurements; bronchial tree segmentation and tracking to determine wall thickness measurements; lung maps based on HU values to help the physician in determining the location and extent of disease across both lungs as well as each lobe.
More Information

Not Found

No
The description focuses on standard image processing techniques like segmentation, tracking, and quantitative analysis (Hounsfield units, volume, wall thickness). There is no mention of AI, ML, deep learning, or any related concepts. The performance studies section also does not describe any training or testing of an AI/ML model.

No.
The device is described as image analysis software and post-processing software that provides quantitative information to aid in diagnosis and management, rather than directly treating or preventing disease.

Yes

Explanation: The "Intended Use / Indications for Use" section explicitly states that the software "may be used in conjunction with CT lung images to aid in the assessment of thoracic disease diagnosis and management." This clearly indicates its role in the diagnostic process.

Yes

The device is described as a "CT, non-invasive image analysis software package" and "CT post-processing software". It operates on existing CT images and is installed on a "GE Advantage Workstation (AW) platform", which is a separate hardware component. The 510(k) summary focuses entirely on the software's functionality and performance, without mentioning any accompanying hardware developed or included with the software itself.

Based on the provided information, this device is NOT an IVD (In Vitro Diagnostic).

Here's why:

  • IVD Definition: In Vitro Diagnostics are medical devices used to examine specimens taken from the human body (like blood, urine, tissue) to provide information about a person's health.
  • Thoracic VCAR's Function: Thoracic VCAR is a software package that analyzes medical images (CT scans) of the thoracic region. It does not analyze biological specimens taken from the body.
  • Intended Use: The intended use clearly states it's for use with "CT lung images" to aid in the assessment of thoracic disease. This is image analysis, not in vitro testing.

Therefore, Thoracic VCAR falls under the category of medical image analysis software rather than an In Vitro Diagnostic device.

N/A

Intended Use / Indications for Use

Thoracic VCAR is a CT, non-invasive image analysis software package, which may be used in conjunction with CT lung images to aid in the assessment of thoracic disease diagnosis and management. The software will provide automatic segmentation of the lungs and automatic segmentation and tracking of the airway tree.
The software will provide quantification of Hounsfield units and display by color the thresholds within a segmented region.

Product codes (comma separated list FDA assigned to the subject device)

90LLZ

Device Description

Thoracic VCAR is a CT post-processing software for the GEAdvantage Workstation (AW) platform. It is designed for the analysis and processing of volumetric CT chest data. It provides quantitative information to aid in the assessment of respiratory diseases. The primary features of the software are: lung and lobe segmentation to obtain threshold based volume measurements; bronchial tree segmentation and tracking to determine wall thickness measurements; lung maps based on HU values to help the physician in determining the location and extent of disease across both lungs as well as each lobe.

Mentions image processing

Yes

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

CT lung images, volumetric CT chest data

Anatomical Site

Thoracic, lung, lobe, bronchial tree

Indicated Patient Age Range

Not Found

Intended User / Care Setting

Physician / Not Found

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)

Summary of Non-Clinical Tests:
THORACIC VCAR complies with DICOM Standard NEMA PS 3.1 - 3.18(2008). The following quality assurance measures were applied to the development of the system:
Risk Analysis
Requirements Reviews
Design Reviews
Performance testing (Verification)
Safety testing (Verification)
Final acceptance testing (Validation)

Summary of Clinical Tests:
The subject of this premarket submission, THORACIC VCAR, did not require clinical studies to support substantial equivalence.

Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)

Not Found

Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.

K083227: Vida Pulmonary Workstation 2, K071513: Syngo InSpace 4D

Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.

Not Found

Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).

Not Found

§ 892.2050 Medical image management and processing system.

(a)
Identification. A medical image management and processing system is a device that provides one or more capabilities relating to the review and digital processing of medical images for the purposes of interpretation by a trained practitioner of disease detection, diagnosis, or patient management. The software components may provide advanced or complex image processing functions for image manipulation, enhancement, or quantification that are intended for use in the interpretation and analysis of medical images. Advanced image manipulation functions may include image segmentation, multimodality image registration, or 3D visualization. Complex quantitative functions may include semi-automated measurements or time-series measurements.(b)
Classification. Class II (special controls; voluntary standards—Digital Imaging and Communications in Medicine (DICOM) Std., Joint Photographic Experts Group (JPEG) Std., Society of Motion Picture and Television Engineers (SMPTE) Test Pattern).

0

Image /page/0/Picture/0 description: The image shows the General Electric (GE) logo. The logo consists of the letters 'G' and 'E' intertwined in a stylized, cursive font. The letters are enclosed within a circle, and there are decorative swirls or flourishes around the outer edge of the circle.

: : GE Healthcare

K103480

510(k) Premarket Notification Submission

510(k) Summary

In accordance with 21 CFR 807.92 the following summary of information is provided:

Date:November 24, 2010
Submitter:GE Healthcare, (GE Medical Systems LLC)
3000 Grandview Blvd
Waukesha Wisconsin 53188
Primary Contact Person:Stephen G. Slavens, RAC
Global Regulatory Affairs Director
GE Healthcare, (GE Medical Systems LLC)
TEL: (262) 548-4992
FAX: (262) 548-3884
Secondary Contact Person:Helen Peng
Regulatory Affairs Leader
GE Healthcare, (GE Medical Systems LLC)
TEL: (262) 548-5091
FAX: (262) 548-3884
Device Trade Name:THORACIC VCAR
Device Common Name:THORACIC VCAR
Classification Names:21CFR 892.2050 Picture archiving and communications system
Product Code:90LLZ
Predicate Device(s):K083227: Vida Pulmonary Workstation 2
K071513: Syngo InSpace 4D
Device Description:Thoracic VCAR is a CT post-processing software for the GE
Advantage Workstation (AW) platform. It is designed for the
analysis and processing of volumetric CT chest data.
It provides quantitative information to aid in the assessment of
respiratory diseases.
The primary features of the software are: lung and lobe
segmentation to obtain threshold based volume measurements;
bronchial tree segmentation and tracking to determine wall
thickness measurements; lung maps based on HU values to help the
physician in determining the location and extent of disease across
both lungs as well as each lobe.
Intended Use:Thoracic VCAR is a CT, non-invasive image analysis software
package, which may be used in conjunction with CT lung images to
aid in the assessment of thoracic disease diagnosis and management.
The software will provide automatic segmentation of the lungs and
automatic segmentation and tracking of the airway tree.
The software will provide quantification of Hounsfield units and
display by color the thresholds within a segmented region.
Technology:THORACIC VCAR provides same type of images and results as its
predicate devices. Main features include:
lung and lobe segmentation lung and lobe volume measurements bronchial tree segmentation and tracking bronchial wall thickness measurements lung maps based on HU values The THORACIC VCAR employs the same fundamental scientific
technology as its predicate devices.
Determination of
Substantial Equivalence:Summary of Non-Clinical Tests:
THORACIC VCAR complies with DICOM Standard NEMA PS 3.1
  • 3.18(2008). The following quality assurance measures were
    applied to the development of the system:
    Risk Analysis Requirements Reviews Design Reviews Performance testing (Verification) Safety testing (Verification) Final acceptance testing (Validation) Summary of Clinical Tests:
    The subject of this premarket submission, THORACIC VCAR, did
    not require clinical studies to support substantial equivalence. |
    | Conclusion: | GE Healthcare considers THORACIC VCAR to be as safe, as
    effective, and performance is substantially equivalent to the
    predicate devices. |

1

Image /page/1/Picture/0 description: The image shows the General Electric (GE) logo. The logo consists of the letters "GE" intertwined in a stylized, cursive font. The letters are enclosed within a circle, and there are small, teardrop-shaped elements around the perimeter of the circle, adding a decorative touch to the design.

· ·

:

510(k) Premarket Notification Submission

.

. . . .

2

Image /page/2/Picture/0 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized depiction of an eagle or bird-like figure with three curved lines representing its body and wings. The logo is surrounded by a circular border containing the text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" in capital letters.

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration 10903 New Hampshire Avenue Document Control Room - WO66-G609 Silver Spring, MD 20993-0002

Mr. Stephen Slavens Regulatory Affairs Director, MI & CT GE Medical Systems, LLC 3000 N. Grandview Blvd. WAUKESHA WI 53188

MAR - 7 2011

Re: K103480

Trade/Device Name: THORACIC VCAR Regulation Number: 21 CFR 892.2050 Regulation Name: Picture archiving and communications system Regulatory Class: II Product Code: LLZ Dated: February 21, 2011 Received: February 24, 2011

Dear Mr. Slavens:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further . announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of

3

medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely Yours,

Mairy S Postel

Mary Pastel, ScD. Director Division of Radiological Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health

Enclosure

4

Indications for Use

510(k) Number (if known): K103480

Device Name: THORACIC VCAR

Indications for Use:

Thoracic VCAR is a CT, non-invasive image analysis software package, which may be used in conjunction with CT lung images to aid in the assessment of thoracic disease diagnosis and management. The software will provide automatic segmentation of the lungs and automatic segmentation and tracking of the airway tree.

The software will provide quantification of Hounsfield units and display by color the thresholds within a segmented region.

Prescription Use X (Part 21 CFR 801 Subpart D) AND/OR

Over-The-Counter Use (21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

Mary S Pastel

(Division Sign-Off) Division of Radiological Devices Office of In Vitro Diagnostic Device Evaluation and Safety

103480 510(k) Number

Page 1 of _ l _ _ l